Screening antibody-antigen interactions in parallel using Biacore A100.
Label-free optical biosensor technology has become a standard tool for characterizing monoclonal antibodies for therapeutic and diagnostic applications. The availability of high-quality binding data at an early stage greatly improves the ability to select antibodies for further development. This article shows how Biacore A100, a protein interaction array system, is capable of providing high-quality data with increased throughput. In a 12-h automated run, we analyzed 386 crude hybridoma samples to identify those with the desired kinetic profiles. Selected antibodies were further characterized by higher resolution analysis, and binding interactions were studied under a range of buffer conditions. We demonstrate how this new parallel processing system significantly expands the throughput of protein interaction analysis while maintaining data quality.
Säfsten
Pär
P
Biacore AB, SE-75450 Uppsala, Sweden.
Klakamp
Scott L
SL
Drake
Andrew W
AW
Karlsson
Robert
R
Myszka
David G
DG
D000818:Animals; D000911:Antibodies, Monoclonal / Q000032:analysis* / Q000276:immunology; D000937:Antigen-Antibody Reactions; D015374:Biosensing Techniques / Q000295:instrumentation* / Q000379:methods; D002021:Buffers; D006825:Hybridomas / Q000737:chemistry / Q000378:metabolism; D006863:Hydrogen-Ion Concentration; D007700:Kinetics; D051379:Mice; D008815:Mice, Inbred Strains; D008954:Models, Biological; D040081:Protein Array Analysis; D011485:Protein Binding; D013997:Time Factors
D000911:Antibodies, Monoclonal; D002021:Buffers